Thomas Zilli

Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis

Piet Ost, Barbara Alicja Jereczek‐Fossa, Nicholas van As et al. · European Urology · 2015 · 290 citations

Medicine, Oncology, Radiation Oncology +14

Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial

Jean‐Pierre Gérard, N. Barbet, Renaud Schiappa et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 174 citations

Medicine, Oncology, Radiation Oncology +17

Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database

Sébastien Salas, Noémie Resseguier, Jean‐Yves Blay et al. · Annals of Oncology · 2017 · 172 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases

Ulrike Schick, S. Jorcano, Philippe Nouet et al. · Acta Oncologica · 2013 · 156 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy

Elise De Bleser, Barbara Alicja Jereczek‐Fossa, Thomas Zilli et al. · European Urology · 2019 · 139 citations · Full text

Medicine, Oncology, Urology +17